Zhitong Hong Kong stocks have known for a long time | China Settlement Announces Capital Liquidation and Settlement Arrangements during the Vacation Period Huang Renxun: The company's chip sales will double next year

[Today's headlines]

Notice of China Settlement on Securities Fund Liquidation and Settlement Arrangements for the 2026 Mid-Autumn Festival and National Day Market Closing Period

According to the “China Settlement Notice Concerning Liquidation and Settlement Arrangements for Securities Funds During the 2026 Holiday Market Closing Period”, the 2026 Mid-Autumn Festival and National Day Market Closing Period are now notified as follows:

September 23, September 24, September 29, and September 30, 2026 will be the new Hong Kong Stock Connect trading days.

Please refer to the original text for details of the Hong Kong Stock Connect business during the 2026 Mid-Autumn Festival and National Day, the Hong Kong Stock Connect equity registration date correspondence, the B-H to H business in the Shanghai and Shenzhen markets, and the “full circulation” business settlement arrangements for H shares.

[General outlook]

Overnight, all US stocks closed higher, AI hardware stocks, and chip semiconductor stocks surged

Overnight, US stocks closed at 316.14 points, or 0.61%, up 0.61% from the previous trading day; the S&P 500 stock index rose 85.95 points to close at 7637.76 points, or 1.14%; and the Nasdaq Composite Index rose 439.88 points to close at 26418.3 points, or 1.69%.

AI hardware stocks and chip semiconductor stocks surged, the Philadelphia Semiconductor Index rose 3.14%, and tripled the semiconductor ETF-DiRexion surged 10.44%. In terms of individual stocks, Arm rose more than 8%, and Intel rose more than 7%.

The Nasdaq China Golden Dragon Index rose slightly by 0.16% to 5743.62 points. The Hang Seng Index ADR rose. On a proportional basis, it closed at 24757.55 points, up 153.26 points or 0.62% from the Hong Kong closing.

WTI crude oil futures on the New York Mercantile Exchange fell $1.34 for the month, or 1.31%, to close at $101.09 a barrel. COMEX gold futures fell $6.90 for the month's consecutive contracts, or 0.16%, to $4380.6 per ounce.

[Hot Topics Preview]

Chen Maobo: Gold is an important part of the financial ecosystem The Hong Kong Monetary Authority is studying increasing gold holdings

The Zhitong Finance App learned that Hong Kong's Financial Secretary Chan Mao-po said that the Hong Kong Monetary Authority's Exchange Fund has two responsibilities. One is to maintain Hong Kong's financial stability and protect the Hong Kong dollar, and the other is to promote Hong Kong's development as an international financial center. Gold is a very important part of the financial ecosystem, so the Hong Kong Monetary Authority is studying increasing its gold holdings after considering all factors. As for the exact amount of holdings, Chen Maobo said that not many details can be revealed at this time.

Nvidia CEO Huang Renxun: The company's chip sales will double next year

Nvidia CEO Hwang In-hoon said on Thursday local time that as artificial intelligence (AI) further penetrates various industries such as healthcare, manufacturing, and financial services, the company's chip sales next year will double that of this year. In the US stock market, Nvidia's stock price rose more than 2.5%. This is another strong growth forecast recently released by Nvidia, indicating that the company is likely to maintain large-scale growth momentum in the next few quarters. Not long ago, Nvidia revealed that the company expects the revenue growth rate for the fiscal year ending January 2028 to reach 70%, with a revenue scale of about 673 billion US dollars. This forecast also prompted analysts to raise market expectations sharply.

BYD (01211) plans to set up four factories in Europe as a core fulcrum for regional expansion

BYD Co., Ltd. (01211) plans to build four factories in Europe over the long term. BYD hopes to use this to meet local manufacturing regulations that have been introduced one after another and to attract more consumers. On Wednesday evening, Alfredo Altavella, a former business consultant for Fiat Chrysler and BYD in Europe, revealed to reporters at an event in Turin that the company plans to build three vehicle assembly plants and an electric vehicle battery factory in Europe. Altavilla said, “This is not going to happen right away, but it's clear that we must do this if we want to meet our sales targets and meet the requirements of EU regulations.” BYD is in talks with local European car companies and governments to consider buying underutilized idle factories in countries such as France, Spain, and Italy.

LCC Technologies, affiliated with Jingtai Holdings (02228), signed a drug discovery cooperation agreement with Stanford University

The collaboration combines Stanford University's disease biology research with LCC Technologies' automated and AI-driven small molecule drug discovery platform to accelerate and drive the development of new drugs. Under the collaboration, new biological insights from Stanford University's disease biology research will use LCC Technologies' proprietary PACE™ drug discovery platform to assess its potential to develop small molecule therapies. PACE™ combines fragment-based drug discovery, AI-driven computational design, automated synthesis, and iterative design-synthesis-test-analysis (DMTA) cycles.

Kingsley Biotech (01548): Company partners with Lilly TuneLab™

The company entered into an agreement with Lilly TuneLab™ (TuneLab), an AI-driven (AI/machine learning) drug discovery collaboration platform founded by Eli Lilly and Company (NYSE: LLY), a multinational pharmaceutical company listed on the New York Stock Exchange (stock code: LLY)). According to the agreement, the Group will provide wet laboratory services to TuneLab participating companies at preferential rates to help generate experimental data and transform AI predictions into biological evidence data.

Global New Materials International (06616) plans to issue convertible bonds with a total principal amount of 1.3 billion yuan at a premium of about 15.05% and simultaneous redemption of 2026 convertible bonds

The initial exchange price was HK$10.93 per share, a premium of approximately 15.05% over the closing price of HK$9.50 per share reported by the Stock Exchange on September 17, 2026 (the trading day the subscription agreement was signed).

New World Development (00017) plans to split a securities investment fund and independently list it on the Shanghai Stock Exchange

The proposed spin-off (proposed spin-off) would involve the independent listing of a securities investment fund on the Shanghai Stock Exchange and the Shanghai Hong Kong New World Tower (assets), a mixed-use property located at 300 Huaihai Middle Road, Huangpu District, Shanghai (composed of Shanghai K11 Art Mall Shopping Art Center and Shanghai K11 ATELIER New World Tower) as the underlying asset of the securities investment fund.

Xuanzhu Bio-B (02575): Abnormal stock price fluctuations are in preliminary discussions with a party on a potential acquisition

The Board hereby informs that the company is currently in preliminary discussions with a party regarding a potential acquisition. As of the date of this announcement, negotiations are still ongoing. The terms and conditions relating to the potential acquisition have not been implemented, and the Group has not entered into a formal agreement on the potential acquisition as of the date of this announcement. There is no guarantee that a potential acquisition will be implemented or finalized. As a result, a potential acquisition may not necessarily take place.

Sifang Jingchuang (06700): Delayed global sale and listing

Zhitong Finance App News, Sifang Jingchuang (06700) issued an announcement. After considering various factors (including current market conditions), the company has now decided to delay the global sale and proposed listing on the main board of the Hong Kong Stock Exchange Limited.

Electricity sales of power plants affiliated to China Resources Power (00836) increased 9.7% in the first 8 months, and electricity sales of attached wind farms increased by 0.6%, and sales of photovoltaic power plants increased 35.7%

According to the Zhitong Finance App, China Resources Electric Power (00836) announced that in August 2026, the electricity sales volume of the subsidiary power plant was 22,628,047 megawatt-hours, up 2.9% year on year. Among them, the electricity sales volume of the attached wind farm reached 3,969,816 megawatt-hours, an increase of 17.3% year on year; the electricity sales volume of attached photovoltaic power plants reached 1,831,454 megawatt-hours, an increase of 26.4% year on year.

Shanghai Electronics, affiliated with Wall Nuclear Materials (09981), plans to invest in the construction of a production base in Dushan Port Economic Development Zone in Zhejiang

According to Zhitong Finance App, Wall Nuclear Materials (09981) issued an announcement. On September 17, 2026, Shanghai Electronics (an indirect wholly-owned subsidiary of the Company) signed an investment agreement with the Commission. Shanghai Electronics conditionally agreed to invest in the project, and the Commission conditionally agreed to assist Shanghai Electronics in implementing the project after purchasing the land use rights involved in the project through a bidding process.

[Individual stock prices are clear]

Hehuang Pharmaceutical (00013): ATTC authorized GSK agency to indicate that the company's overseas route is clear

On September 3, the company announced that it had reached an exclusive license agreement with GSK for HMPL-A830 (KRAS-EGFR ATTC). GSK received overseas rights with a down payment/milestone of US$1.118 billion. Huafu Securities said it is optimistic that HMPL-A830 is expected to use a differentiation mechanism to enter the CRC's KRAS mutation and is not satisfied with the market. It is recommended to focus on tracking Phase I data readings.

Huatai Securities said that A830 received a major BD, verifying the global value of the ATTC platform. The company's 2H26 is expected to launch Global Phase I, while A251 and A580 Global Phase I are progressing smoothly. Various molecules are expected to enter clinical trials one after another, and they are optimistic that they will continue to go overseas. Previously, the company and MNC such as AstraZeneca and Takeda had reached multiple overseas BDs, and overseas commercialization of related molecules is gradually being implemented. Among them, overseas sales of furoquintinib continued to grow steadily, and obtained the global PFS/III phase of 8M26 sevotinib 2LNSCLC OS is positive, and the FDA is expected to report production.